This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gubareva, L. V.
Right arrow Articles by Hayden, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gubareva, L. V.
Right arrow Articles by Hayden, F. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3403-3408, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3403-3408.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants

Larisa V. Gubareva,1,* Robert G. Webster,2,3 and Frederick G. Hayden1,4

Division of Epidemiology and Virology, Department of Internal Medicine,1 and Department of Pathology,4 University of Virginia School of Medicine, Charlottesville, Virginia, and Department of Virology and Molecular Biology, St. Jude Children's Research Hospital,2 and Department of Pathology, University of Tennessee,3 Memphis, Tennessee

Received 1 February 2001/Returned for modification 2 May 2001/Accepted 28 August 2001

RWJ-270201 is a novel cyclopentane inhibitor of influenza A and B virus neuraminidases (NAs). We compared the ability of RWJ-270201 to inhibit NA activity of clinical influenza isolates and viruses with defined resistance mutations with that of zanamivir and oseltamivir carboxylate. In NA inhibition assays with influenza A viruses, the median 50% inhibitory concentration (IC50) of RWJ-270201 (approximately 0.34 nM) was comparable to that of oseltamivir carboxylate (0.45 nM) but lower than that of zanamivir (0.95 nM). For influenza B virus isolates, the IC50 of RWJ-270201 (1.36 nM) was comparable to that of zanamivir (2.7 nM) and less than that of oseltamivir carboxylate (8.5 nM). A zanamivir-resistant variant bearing a Glu119-to-Gly (Glu119right-arrowGly) or Glu119right-arrowAla substitution in an NA (N2) remained susceptible to RWJ-270201 and oseltamivir carboxylate. However, a zanamivir-selected variant with an Arg292right-arrowLys substitution in an NA (N2) showed a moderate level of resistance to RWJ-270201 (IC50 = 30 nM) and zanamivir (IC50 = 20 nM) and a high level of resistance to oseltamivir carboxylate (IC50 > 3,000 nM). The zanamivir-resistant influenza B virus variant bearing an Arg152right-arrowLys substitution was resistant to each NA inhibitor (IC50 = 100 to 750 nM). The oseltamivir-selected variant (N1) with the His274right-arrowTyr substitution exhibited resistance to oseltamivir carboxylate (IC50 = 400 nM) and to RWJ-270201 (IC50 = 40 nM) but retained full susceptibility to zanamivir (IC50 = 1.5 nM). Thus, drug-resistant variants with substitutions in framework residues 119 or 274 can retain susceptibility to other NA inhibitors, whereas replacement of functional residue 152 or 292 leads to variable levels of cross-resistance. We conclude that RWJ-270201 is a potent inhibitor of NAs of wild-type and some zanamivir-resistant or oseltamivir-resistant influenza A and B virus variants.

* Corresponding author. Mailing address: Department of Internal Medicine, Division of Epidemiology and Virology, University of Virginia, P.O. Box 800473, Charlottesville, VA 22908. Phone: (804) 243-2705. Fax: (804) 982-0384. E-mail: lvg9b{at}virginia.edu.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3403-3408, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3403-3408.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hurt, A. C., Holien, J. K., Parker, M., Kelso, A., Barr, I. G. (2009). Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation. J. Virol. 83: 10366-10373 [Abstract] [Full Text]  
  • Gabbard, J., Velappan, N., Di Niro, R., Schmidt, J., Jones, C.A., Tompkins, S.M., Bradbury, A.R.M. (2009). A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng Des Sel 22: 189-198 [Abstract] [Full Text]  
  • Huang, I-C., Li, W., Sui, J., Marasco, W., Choe, H., Farzan, M. (2008). Influenza A Virus Neuraminidase Limits Viral Superinfection. J. Virol. 82: 4834-4843 [Abstract] [Full Text]  
  • Yen, H.-L., Ilyushina, N. A., Salomon, R., Hoffmann, E., Webster, R. G., Govorkova, E. A. (2007). Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo. J. Virol. 81: 12418-12426 [Abstract] [Full Text]  
  • Yen, H.-L., Hoffmann, E., Taylor, G., Scholtissek, C., Monto, A. S., Webster, R. G., Govorkova, E. A. (2006). Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.. J. Virol. 80: 8787-8795 [Abstract] [Full Text]  
  • Yen, H.-L., Herlocher, L. M., Hoffmann, E., Matrosovich, M. N., Monto, A. S., Webster, R. G., Govorkova, E. A. (2005). Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility. Antimicrob. Agents Chemother. 49: 4075-4084 [Abstract] [Full Text]  
  • Beigel, J. H. (2005). Avian influenza A (H5N1) infection in humans.. NEJM 353: 1374-1385 [Full Text]  
  • Jackson, D., Barclay, W., Zurcher, T. (2005). Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55: 162-169 [Abstract] [Full Text]  
  • Thompson, C. I., Barclay, W. S., Zambon, M. C. (2004). Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. J Antimicrob Chemother 53: 759-765 [Abstract] [Full Text]  
  • McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L. (2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI 11: 21-28 [Abstract] [Full Text]  
  • McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., Zambon, M. (2003). Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir. Antimicrob. Agents Chemother. 47: 2264-2272 [Abstract] [Full Text]  
  • Weinstock, D. M., Gubareva, L. V., Zuccotti, G. (2003). Prolonged Shedding of Multidrug-Resistant Influenza A Virus in an Immunocompromised Patient. NEJM 348: 867-868 [Full Text]  
  • Gubareva, L. V., Nedyalkova, M. S., Novikov, D. V., Murti, K. G., Hoffmann, E., Hayden, F. G. (2002). A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. J. Gen. Virol. 83: 2683-2692 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»